Abstract:Human angiotensin-I-converting enzyme (ACE) is an important target of antihypertensive therapy, which possesses a bulky, hydrophobic pocket that is physicochemically compatible with a wide variety of peptide substrates and small-molecule ligands. Rational design of potent ACE inhibitors has long been an attractive topic in the chemical, biological and medical communities. In the present study, an integrative protocol is described to optimize and modify peptides bound with ACE based on their complex three-dimensional structures. The protocol combines a number of sophisticated computational methods including molecular dynamics (MD) simulation, quantitative structure-activity relationship (QSAR), molecular mechanics/Poisson-Boltzmann surface area (MM-PB/SA) and quantum mechanics/molecular mechanics (QM/MM) to discover new potent ACE-inhibitory peptides. With this strategy hundreds of potential peptides are generated virtually, from which several promising candidates are synthesized and assayed in vitro using a standard Fmoc-protected amino acid solid phase synthesis and spectrophotometric method, respectively. Six peptides are found to have potency against ACE, four of which (LVY, VLKP, MLPVY and LKIPLY) show satisfactory inhibitory capability (pIC(50)=5.84, 5.27, 5.40 and 5.57, respectively). Subsequently, the complex structures of tripeptide LVY and hexapeptide LKIPLY with ACE are computationally modeled and their binding free energies are estimated as -34.2 and -57.8 kcal/mol, respectively, by using a rigorous QM/MM scheme. Intensive steric collisions are observed around the C-terminus of peptide ligands in the bound state. Based upon the findings the C-terminal residues of the two peptides are modified to small, hydrophobic amino acids Val and Ala, resulting in mutated peptides LVA and LKIPVA, respectively. Consequently, a significant improvement in ACE inhibitory activity is observed for the LKIPVA mutant (pIC(50) increases from 5.57 to 6.07), whereas only a modest activity change was associated with the LVA mutant (pIC(50) decreases from 5.84 to 5.80).

Peptidomimetic Star Polymers for Targeting Biological Ion Channels

Design, Synthesis and Functional Validation of Peptide Inhibitors Based on TRPV1 Ion Channel Agonist RhTx.

Pharmaceutical Optimization of Peptide Toxins for Ion Channel Targets: Potent, Selective, and Long-Lived Antagonists of Kv1.3.

Structural Basis of a Potent Peptide Inhibitor Designed for Kv1.3 Channel, a Therapeutic Target of Autoimmune Disease

Design, Synthesis, And Pharmacological Evaluation Of Analogues Derived From The Plev Tetrapeptide As Protein-Protein Interaction Modulators Of Voltage-Gated Sodium Channel 1.6

Engineering a Peptide Inhibitor Towards the KCNQ1/KCNE1 Potassium Channel (Iks)

Toxin Acidic Residue Evolutionary Function-Guided Design of De Novo Peptide Drugs for the Immunotherapeutic Target, the Kv1.3 Channel

Designer and natural peptide toxin blockers of the KcsA potassium channel identified by phage display

Integrating Computational Modeling and Experimental Assay to Discover New Potent Ace-Inhibitory Peptides

Opto-chemogenetic inhibition of L-type CaV1 channels in neurons through a membrane-assisted molecular linkage

Artificial Channels Based on Bottlebrush Polymers: Enhanced Ion Transport Through Polymer Topology Control

Structural Insights into the Atomistic Mechanisms of Action of Small Molecule Inhibitors Targeting the KCa3.1 Channel Pore

Computational engineering of water-soluble human potassium ion channels through QTY transformation

Two types of peptides derived from the neurotoxin GsMTx4 inhibit a mechanosensitive potassium channel by modifying the mechanogate

Design, Synthesis and Mechanism of Action of Novel Μ-Conotoxin KIIIA Analogs for Inhibition of the Voltage-Gated Sodium Channel Nav1.7.

Modulation of Lymphocyte Potassium Channel KV1.3 by Membrane-Penetrating, Joint-Targeting Immunomodulatory Plant Defensin

Antibodies and venom peptides: new modalities for ion channels

Identification and Optimization of 2‐aminobenzimidazole Derivatives As Novel Inhibitors of TRPC4 and TRPC5 Channels

Mechanisms Underlying the Inhibition of KV1.3 Channel by Scorpion Toxin ImKTX58

Foldamer-Based Potassium Channels with High Ion Selectivity and Transport Activity

Design, synthesis, and mechanism of action of novel μ-conotoxin KIIIA analogues for inhibition of the voltage-gated sodium channel Nav1.7